Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice

  • PDF / 536,891 Bytes
  • 7 Pages / 595.28 x 793.7 pts Page_size
  • 98 Downloads / 176 Views

DOWNLOAD

REPORT

RESEARCH

Open Access

Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice Howard Meng and Lars Grosse-Wortmann*

Abstract Background: The association of gadolinium-based contrast agents (GBCAs) with nephrogenic systemic fibrosis (NSF) has led to a heightened awareness towards patients’ renal function. Whereas detailed guidelines exist for the use of GBCAs in adult patients, best practice is less well defined in children, especially in the very young. We aimed at identifying current practice with regards to the use of GBCAs in children who undergo Cardiovascular Magnetic Resonance. Methods: We conducted a worldwide survey among cardiac imagers with pediatric expertise. The questionnaire contained 21 questions covering the imagers’ work environments, GBCAs used, monitoring of renal function, and a special emphasis was placed on the practice in neonates. Results: The survey yielded 70 replies. The single most commonly used GBCA was gadopentetate dimeglumine 34/70 (49%). Among the respondents, the choice of GBCA was more importantly based on availability 26/70 (37%) and approval by a pharmaceutical licensing body that most closely reflects the indication 16/70 (23%) than image quality 7/70 (10%) and side effect profile 8/70 (11%). 55/70 (79%) of respondents performed scans in neonates

Data Loading...

Recommend Documents
Recommendations: What We Know and What We Can Do

205 103 3MB

Data on Gun Violence: What Do We Know and How Do We Know It?

206 39 5MB

The facilitative glucose transporter GLUT12: what do we know and what would we like to know?

179 85 412KB

What we need to know, where we need to go

223 48 86KB

Pseudo-Likelihood or Quadrature? What We Thought We Knew, What We Think We Know, and What We Are Still Trying to Figure

222 94 508KB

How Do We Know? Measuring Impact

230 16 4MB

Psychological Intervention and COVID-19: What We Know So Far and What We Can Do

194 101 624KB

The Role of Executive Cognitive Functions in Changing Substance Use: What We Know and What We Need to Know

177 10 198KB

Management of Achilles and patellar tendinopathy: what we know, what we can do

202 48 8MB

What We Know and What We Believe: Lessons from cognitive psychology

175 73 119KB

How to Prevent Injuries in Alpine Ski Racing: What Do We Know and Where Do We Go from Here?

222 60 729KB

What Do We Know about Antibiotics in the Environment?

168 32 2MB